- ABOUT US
Precision & Predictability
The LENSAR Difference
- CERTIFICATES & SUPPLIES
- PRACTICE SUPPORT
Get In Touch
Nicholas T. Curtis
CEO, LENSAR, Inc.
William J. Link, Ph.D.
Chairman of the Board
Richard L. Lindstrom
John P. McLaughlin
Gary M. Winer
Nicholas T Curtis, CEO
Nicholas T. Curtis’ joined LENSAR, Inc., in 2010, and has been a board member and Chief Executive Officer since 2012. His rich career in ophthalmology spans 35 years, which has given him unique insights and perspectives that have helped him shape his vision for LENSAR, Inc., the leader in next-generation femtosecond laser technology for refractive cataract surgery.
Of note, as a founding member of the ophthalmic subsidiary of Chiron Corporation, Mr. Curtis has participated in the evolution of many of ophthalmology's major trends including anterior to posterior segment IOLs, cataract surgery procedures from intracapsular to extracapsular and phacoemulsification to femtosecond, and refractive surgery from RK to ALK to LASIK.
Before LENSAR, Mr. Curtis founded Refractive Surgical Resources in 1996, a pioneering company providing transportable surgical services, which was acquired by Laser Vision Centers, Inc., in 1998. He also served as the Senior Vice President of Sales and Marketing for STAAR Surgical Company and was Chief Commercial Officer at WaveTec Vision, just prior to joining LENSAR.
Mr. Curtis holds a B.S. in communications from Northwestern University.
A message from the CEO
“Femtosecond refractive laser cataract technology represents one of the most profound enhancements to cataract surgery in many years. When offering cataract surgeons new options, there can be confusion about what criteria is critical in evaluating a potential system. Cataract surgeons must consider a femtosecond laser system’s imaging technology, patient interface, ergonomics, impact on efficiency and patient flow, and transparency of available clinical data.
The platform must have the potential to improve surgical outcomes and safety, help surgeons manage the complexities of astigmatism, all the while decreasing complications. It must, in particular, automate and provide greater precision and reproducibility in sizing, shape, and placement of the capsulorhexis in order to better position the IOL, improve fit, and optimize patient refractive outcome. The surgeon should also choose a device to eliminate or substantially reduce the cumulative dissipated energy (CDE) required with conventional ultrasound to complete the removal of the cataract regardless of its hardness.
LENSAR’s rigorous attention to detail has resulted in the LENSAR Cataract Laser System with Augmented Reality Imaging, the only true 3D imaging and treatment based on the patients’ actual biometric measurements, treating anatomical or docking tilt and centration. And now with available Streamline software enhancements, LENSAR provides unprecedented guidance to help surgeons effectively manage astigmatism. The team at LENSAR is proud to offer a femtosecond laser cataract system that will meet and exceed cataract surgeons' expectations, not only today, but also in the future.”
William J. Link
William J. Link, Ph.D., who specializes in early-stage investing in medical devices, is a Founder and Managing Partner of Flying L Partners and a Founder and Managing Director of Versant Ventures. Prior to cofounding Versant Ventures, Dr. Link was a general partner at Brentwood Venture Capital and has over two decades of operations experience in the healthcare industry.
Previously, Dr. Link served as Founder, Chairman, and CEO of Chiron Vision, which was sold to Bausch and Lomb in 1997. Before his time with Chiron Vision, Dr. Link founded and served as President of American Medical Optics (AMO), a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the Board of AMO’s successor company, Advanced Medical Optics (AMO), which was acquired by Abbott in 2009 and then by Johnson and Johnson in 2016. Before entering the healthcare industry, Dr. Link was an Assistant Professor in the Department of Surgery at the Indiana University School of Medicine.
In addition to serving as the LENSAR Chairman of the Board, Dr. Link also serves on the board of directors of several private companies and three public companies: Edwards Lifesciences, Glaukos, and Second Sight Medical Products.
Dr. Link holds a B.S., M.S., and Ph.D. from Purdue University.
Richard L. Lindstrom, M.D.
Richard L. Lindstrom, M.D., is the founder and attending surgeon at Minnesota Eye Consultants, an Adjunct Clinic Professor Emeritus at the University of Minnesota Department of Ophthalmology, and a visiting professor at the UC Irvine Gavin Herbert Eye Institute. He is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive, glaucoma, and laser surgery. Throughout his career he has also been recognized as a researcher, teacher, inventor, writer, lecturer, physician, and surgeon.
From 2007 to 2008, Dr. Lindstrom served as President of the American Society of Cataract and Refractive Surgery (ASCRS) and continues to serve on the ASCRS Executive Committee and its Foundation. He has also served as President of the International Society of Refractive Surgery of the American Academy of Ophthalmology, the International Intraocular Implant Club, and the International Refractive Surgery Club.
In addition to serving on the LENSAR board, Dr. Lindstrom currently serves on the board of directors for numerous companies including Lindstrom Restoration, Minnesota Eye Consultants, TearLab, Ocular Therapeutix, Imprimis, and Refractec. He also serves on several not-for-profit and journal editorial boards.
Dr. Lindstrom received his undergraduate degree and M.D. from the University of Minnesota. He also conducted his residency and fellowship training specializing in the cornea at the University of Minnesota and affiliated hospitals. He then extended his anterior segment surgery fellowship training at Mary Shiels Hospital in Dallas, followed by a fellowship in glaucoma at University Hospital in Salt Lake City.
John P. McLaughlin
John P. McLaughlin served as the Chief Executive Officer of PDL BioPharma, Inc., from December 2008 until December 2019. He was the Chief Executive Officer and a director of Anesiva, Inc., formerly known as Corgentech, Inc., a publicly-traded biopharmaceutical company, from January 2000 to June 2008.
From December 1997 to September 1999, Mr. McLaughlin was President of the biopharmaceutical company Tularik, Inc. He held a number of senior management positions at Genentech, Inc., between 1987 to 1997, including Executive Vice President. Prior to Genentech, Mr. McLaughlin was a partner at a Washington, D.C. law firm specializing in food and drug law. He also served as counsel to various subcommittees of the United States House of Representatives, during which time he drafted numerous measures that became Food and Drug Administration laws.
In addition to serving on the LENSAR board, Mr. McLaughlin is a longstanding member of the PDL board and serves on the board of directors for Noden, a private company that commercializes two global hypertension drugs. He also cofounded and served as Chairman of the board of Eyetech Pharmaceuticals, Inc., and cofounded and served as a director of Peak Surgical, Inc. Mr. McLaughlin also spent time as a director of several other biopharmaceutical companies: AxoGen, Inc., Adverum Biotechnologies, Inc., and Seattle Genetics, Inc.
Mr. McLaughlin holds a B.A. from the University of Notre Dame and a J.D. from the Catholic University of America.
Gary M. Winer
Gary M. Winer is the President and CEO of ORGENTEC Diagnostika, a private equity owned specialty manufacturer of autoimmune and infectious disease diagnostic tests. He is also the Principal for DRC Health Care Advisors, a consulting firm for clients in biopharma, medical device, and diagnostic health sectors, with a focus on business strategy, product and portfolio planning, and commercialization in international markets.
For over 25 years, Mr. Winer has been proving his leadership abilities in the healthcare and biopharmaceutical industry on an international platform that includes such notable markets as the United States, Europe, Latin America, Asia, and Japan. During his career, Mr. Winer made significant leadership impact for such Fortune 100 Companies as AbbVie, Abbott Laboratories, and Pfizer. He served as Divisional Vice President for Abbott’s Latin America and Canadian diagnostic business unit, Divisional Vice President for Abbott’s U.S. Commercial Operations, and Corporate Vice President and President for Abbott Japan. He continued to lead AbbVie Japan as their Executive President and CEO after managing the separation from Abbott.
In addition to serving on the board for LENSAR, Mr. Winer also serves on the board for three private healthcare companies: Schedule 1 Therapeutics, SmartHealth Activator, and Chroma Corporation.
Mr. Winer holds a B.S. from California State University and an M.B.A. from Northwest University’s Kellogg Graduate School.
Mitchell A Jackson,
Mark Packer, M.D.,
Gregory D. Parkhurst,
Robert J. Weinstock,
Carlos Buznego, M.D.
Carlos Buznego, M.D., is a Miami-based board-certified ophthalmologist specializing in a range of ophthalmic surgeries including LASIK, laser cataract, and micro-invasive glaucoma surgery. He is an active staff member at Baptist Hospital, Surgical Park Center, and Baptist Medical Arts Surgery Center, as well as a voluntary assistant professor of ophthalmology at the University of Miami’s Bascom Palmer Eye Institute and the Florida International University College of Medicine. Dr. Buznego has been recognized by the American Academy of Ophthalmology for his achievements and has been named one of the “Best Doctors in South Florida” in several polls over the last decade.
Early in his career, he was elected the youngest President in history of the Dade County Medical Association (2001-2002) and the youngest and first Hispanic President of the Florida Society of Ophthalmology. Today, Dr. Buznego is the Chairman of the board of CEDARS/ASPENS. He is also an international lecturer, writes articles about new techniques in his areas of expertise, and is an active clinical researcher and investigator for numerous FDA clinical trials.
Dr. Buznego earned his bachelor’s degree and M.D. at Washington University in St. Louis and completed his training in ophthalmology at the prestigious Bascom Palmer Eye Institute.
Mitchell A. Jackson, M.D.
Mitchell A Jackson, M.D., is a board-certified ophthalmologist specializing in cataract and refractive surgery. He is the founder and CEO of Jacksoneye, his private practice of more than 25 years in Lake Villa, Illinois. Additionally, he is a clinical assistant at the University of Chicago Hospitals. Dr. Jackson has been widely recognized for his achievements, having been selected to the PS250 Premier Surgeon list, OSN300 Refractive Surgeon list, and ASCRS Clinical Subcommittee for Cataract and Refractive Surgery. He also received the 2018 Annual Millennial Award, the 2018 AAO Board of Trustees Achievement Award, and the 2018 Innovation and Founders Award for CEDARS/ASPENS.
Dr. Jackson is a board member of the American College of Eye Surgeons, founding member of the American College of Ophthalmic Surgeons, and founding member and past 2018 President of CEDARS/ASPENS. He also serves on the editorial boards of numerous ophthalmology publications. Dr. Jackson has been involved in many FDA pharmaceutical and surgical clinical studies over the tenure of his practice, including serving as the Global Medical Director of ACE Vision Group.
Dr. Jackson graduated from Pomona College, received his medical degree from the Chicago Medical School, and completed his ophthalmology residency at the University of Chicago Hospitals.
Mark Packer, M.D., F.A.C.S., C.P.I.
Mark Packer, M.D., F.A.C.S., C.P.I., is an internationally recognized leader in ophthalmology and board-certified ophthalmologist. He is an author of original research establishing innovative techniques and groundbreaking technologies and is widely sought for his clinical, medical, and regulatory expertise in ophthalmic drugs and devices. Dr. Packer consults for a multitude of companies and is the Chief Medical Officer for Cassini Technologies and International Biomedical Devices, Inc. He has been awarded for his contributions and leadership in the field, including a Special Recognition Award and an Achievement Award from the American Academy of Ophthalmology.
Dr. Packer has edited textbooks on cataract and refractive lens surgery, written hundreds of book chapters and medical articles, and served as editor for the annual cataract and IOL issue of Current Opinion in Ophthalmology. Elected to membership in the International Intraocular Implant Club (2005), he has delivered hundreds of presentations at scientific meetings around the globe and demonstrated live cataract surgery at conferences worldwide. Additionally, he has served as Principal Investigator or Medical Monitor in over 60 clinical trial protocols that led to FDA clearances and approvals.
Dr. Packer completed his general studies at Harvard University and earned his M.D. from the University of California, Davis, School of Medicine. He completed his residency at Boston University Affiliated Hospitals.
Gregory D. Parkhurst, M.D., F.A.C.S.
Greg Parkhurst, M.D., is the founder and Physician-CEO of Parkhurst NuVision, a rapidly growing ophthalmology group in San Antonio, Texas. Parkhurst NuVision is known internationally as a leading practice in refractive surgery. Listed as one of the Top 40 Under 40 most influential ophthalmologists in the world by The Ophthalmologist, Dr. Parkhurst has helped bring new vision correction procedures to market through research and innovation.
Dr. Parkhurst has been a founding member of multiple ophthalmic professional societies including the American European Congress of Ophthalmic Surgery and the Refractive Surgery Alliance, for which he also served as President for 2 years. He has served as principal investigator for numerous FDA clinical trials, which have led to FDA approvals of some of the most commonly used surgical procedures in ophthalmology today. Dr. Parkhurst has particular expertise with phakic IOLs, having been the highest volume Visian ICL implanter in the U.S. for 2 consecutive years, and has authored multiple papers and text book chapters on the subject.
Dr. Parkhurst earned his M.D. from Northwestern University. He completed his residency at Walter Reed Army Medical Center and fellowship at the University of Texas and Slade and Baker Vision Center in Houston.
Denise Visco, M.D.
Denise Visco, M.D., is an award-winning ocular surgeon and Medical Director. She is the founder of Eyes of York (1996), as well as a freestanding laser vision correction center, also in Pennsylvania. In addition to being certified by the American Board of Ophthalmology, she is among the few elite providers certified by the American Board of Eye Surgery, having performed more than 20,000 no-stitch cataract surgeries and thousands of laser vision correction procedures. In recognition of her leadership and innovation in the field of ophthalmology, Dr. Visco has been named to the prestigious Ocular Surgery News’ Premier Surgeon 300.
Dr. Visco is a pioneer of surgical advancement, as she was the first female surgeon in the world to perform cataract surgery with the LENSAR Laser System. She is also the first in her area to offer all laser LASIK procedures and customized options for cataract surgery, and she opened York County’s first and only ambulatory surgical center specializing in eye surgery. Dr. Visco is a founding member and board member of CEDARS/ASPENS, as well as President of the American College of Eye Surgeons.
Dr. Visco graduated with honors from the University of Delaware, Jefferson Medical College, and Penn State University.
Robert J. Weinstock, M.D.
Robert J. Weinstock, M.D., is a board-certified ophthalmologist and fellowship-trained cataract and refractive surgeon who has performed over 30,000 cataract and refractive procedures. Dr. Weinstock currently serves as the Director of Cataract and Refractive Surgery at the Eye Institute of West Florida and the Weinstock Laser Eye Center. Dr. Weinstock is also an associate clinical professor at the University of South Florida’s Department of Ophthalmology. He is a world leader and innovator in cataract surgery, having helped develop numerous revolutionary technologies such as microincisional bimanual phaco, intraoperative aberrometry, 3-D surgical guidance, and femtosecond laser cataract surgery.
Additionally, Dr. Weinstock is the Chief Medical Editor for Cataract and Refractive Surgery Today and is on the board of Outpatient Ophthalmic Surgery Society and the CEDARS/ASPENS organization. He also serves on the medical advisory board of many ophthalmic companies. Dr. Weinstock is actively involved in FDA phase III and IV clinical trials, is a well-published author and frequent lecturer, and continues to teach students internationally.
Dr. Weinstock earned his B.A. from Brandeis University and his M.D. from the Chicago Medical School. He completed his residency at the Saint Louis School of Medicine and fellowship at the Eye Institute of West Florida.
Elizabeth Yeu, M.D.
Elizabeth Yeu, M.D., is a board-certified ophthalmologist specializing in cornea, cataract, LASIK, and refractive surgery. Dr. Yeu has been a partner at Virginia Eye Consultants since 2014 and is an assistant professor at the Eastern Virginia Medical School. She is also the Medical Director of the Virginia Surgery Center and serves on the board for the Virginia Eye Foundation. She has been well awarded for her contributions to ophthalmology, with recognitions that include The Ophthalmologist's global Power Lists (2017, 2019) and their Top 40 Under 40 (2015), Clinical Rising Star (2018) by the Ophthalmic Innovations Summit, Castle Connelly Top Doctor (2016-2019), and the Castle Connelly Exceptional Women in Medicine Award (2017, 2018).
Dr. Yeu provides guidance and governance across several national medical boards and committees. She has authored numerous articles and is a frequent lecturer in the areas of refractive cataract surgery, anterior segment reconstruction, ocular surface disease management, and surgical management of astigmatism. She is the editor-in-chief of U.S. Ophthalmic Review and served as the medical editor of Millennial Eye (2015-2017).
Dr. Yeu completed her medical degree at the University of Florida College of Medicine, her residency at Rush University Medical Center in Chicago, and her fellowship at Cullen Eye Institute, Baylor College of Medicine.